

Review

Promoter elements in endocrine pancreas development and hormone regulation

C. Brink

Biozentrum, Klingelbergstrasse 70, 4056 Basel (Switzerland), e-mail: christopher.brink@unibas.ch

Received 12 September 2002; received after revision 8 October 2002; accepted 11 October 2002

Abstract. The research upon the genetics of mammalian endocrine pancreas development gave rise to the detection of several genes that mediate decisions between different cell lineages that finally lead to four different hormone-producing cell types. Transcription factors such as *Pdx1*, *Hnf6*, *ngn3*, *NeuroD/BETA2*, *Pax6* or *Pax4* act within regulatory cascades and networks of transcriptional regulations that provide the genetic background for endocrine pancreas development. In adult animals the anatomical unit of the endocrine organ, the Islets of Langerhans, is built out of α , β , δ and PP cells producing the peptide hormones glucagon, insulin, somatostatin and pancreatic

polypeptide, respectively. Numerous promoter analyses of genes expressed in endocrine cells during development and adulthood have been performed. It turns out that the sequences of cis-regulatory elements within promoters of both, developmental control genes and peptide hormones, can show significant similarities. The relevance of such elements has been demonstrated by several deletion experiments and protein-DNA interaction assays. This review summarizes the currently known cis-regulatory elements that are important for islet development and provides the opportunity of detecting further pancreatic genes by discussing common promoter structures.

Key words. Pancreas; gene regulation; promoters; endocrine development; Islets of Langerhans; glucagon; insulin; β cells; α cells.

Introduction

The development of individual organisms is based on genetic regulation and interaction. The underlying genetic process, namely the control of gene activity, begins with the very first step of gene expression, transcription of DNA. Accordingly, influencing the activity of the responsible enzyme, RNA polymerase II and its cofactors, evolved as a critical mechanism in gene regulation. Thus tight control of the genetic network underlying ontogenesis, and gene-regulated formation of complex organs and structures was established throughout evolution. One example of such a structure are the pancreatic Islets of Langerhans, which represent the endocrine subunit of a complex organ [1–3].

The main compartment of the pancreas is exocrine tissue. It is anatomically organized as acini that produce digestive

enzymes and release them into the duodenum. The endocrine units of the organ, the Islets of Langerhans, are embedded in exocrine tissue and contain four distinct cell types. The great majority of islet cells are centrally positioned insulin-producing β cells. In the periphery, glucagon-producing α cells, somatostatin-secreting δ cells and PP cells for synthesizing pancreatic polypeptide are found. These hormones mediate regulation of blood-glucose levels.

The genetic regulation that underlies endocrine pancreas development is still under intensive investigation. The first-known major step initiating pancreatic organogenesis is an induction event. The notochord touches the duodenum, and mesodermal activin repels endodermal *Shh* activity [4–6]. This allows *Pdx1* expression to mark duodenal cells, which later in development give rise to the dorsal pancreatic outgrowth. A second, ventral out-

growth, however, is induced differently, since it is independent of the notochord [7–9]. Upon activation of *Pdx1*, other genes, e.g. *Hlxb9*, *Hnf6*, *Foxa1*, *Foxa2*, *Hnf1 α* , *ngn3*, *NeuroD/BETA2*, *Pax6*, *Pax4*, *Nkx2.2*, *Nkx6.1*, *Mist1* and *p48*, influence further cell fate decisions within the developing organ [10–25]. For example, the choice between duodenal and exocrine cell fate is influenced by *p48* [26]; *Hnf6*, *ngn3*, *NeuroD/BETA2* and *Pax6* mediate the switch between an exocrine and endocrine cell fate [27]. Since all of the genes mentioned are transcription factors, they operate by binding to regulatory DNA sequences of target-gene promoters [28–32].

The genetic information of an individual is identical within every single cell of an organism. As a consequence, a distinct pattern of transcription factor expression dictates the fate of a given cell by acting on cis-regulatory DNA sequences. Consequently, it is possible to deduce a cell's determination and differentiation status from its observed gene expression pattern. The chain links between this regulatory environment and the executive genes are cis-regulatory elements of genes, and the investigation of gene interactions leading to distinct cell fates will always include research about the according cis-regulatory elements. This review summarizes the scientific results currently available concerning direct gene interactions during endocrine pancreas development and function, emphasizing apparently conserved promoter structures of endocrine genes.

The dual task of *Pdx1*

During pancreatic organ genesis, the homeodomain transcription factor *Pdx1* represents the most important factor for regulation of pancreas development among the currently known genes [2]. Disruption of the *Pdx1*-gene leads to a loss of exocrine as well as endocrine tissue [8, 9]. Together with *Hlxb9* its expression domain appears in the duodenum early in development [8–11] and marks a population of cells that represent the earliest pancreatic precursors [33, 34]. Once activated, *Pdx1* mediates expression of a huge variety of continuative factors [35, 36]. Some of them subsequently are necessary to demarcate distinct cell lineages [20, 21, 27]. To date, direct regulation of three transcription factors by *Pdx1* protein has been described (fig. 1). Cis-regulatory elements that mediate pancreas-specific expression of *Pax4*, *Nkx6.1* and of *Pdx1* itself are regulated by *Pdx1* protein [37–41].

Considering *Pdx1* as a gene on top of a genetic regulatory cascade governing pancreas development – comparable to *Pax6* in eye morphogenesis – it might be expected to directly activate even more transcription factors that are responsible for further fate decisions later in development. However, no direct regulation even of promising candidates such as *Hlxb9*, *Hnf6* or *ngn3* by *Pdx1* has yet been reported.




Figure 1. The dual task of *Pdx1*. Early interactions. *Pdx1* has been shown to interact with cis-regulatory elements of transcription factors (*Pdx1*, *Pax4*, *Nkx6.1*) as well as of peptide hormones (IAPP, insulin, glucagon). Activin, repressing endodermal *Shh*, enables *Pdx1* expression in early development. After initiating pancreas development, *Pdx1* participates in regulation of glucose-dependent insulin response in mature β cells.

On the other hand, many data exist regarding *Pdx1*-mediated transcriptional control of peptide hormones in the mature organ (fig. 1). This is the second task of the pancreatic *Pdx1* gene. After initiating pancreas development and being expressed in pancreatic precursors in general, *Pdx1* activity is restricted to β and δ cells [42, 43]. In these cells the protein becomes assigned to tasks concerning cell function throughout adulthood [35, 44–46]. For example, *Pdx1* regulates the cell-specific and glucose-dependent hormone production of insulin [47–49], islet amyloid polypeptide (IAPP) [50, 51] and other factors [52–54].

This dual-task existence makes *Pdx1* an especially interesting candidate gene to investigate the principles of gene regulation. Since *Pdx1* governs early developmental processes as well as function of the mature endocrine pancreas, a regulatory circuit can be proposed. Genes that have been directly or indirectly activated by *Pdx1* will later in development have to tightly control *Pdx1* itself to orchestrate glucose homeostasis. Interestingly, during the islet regeneration process – most probably from duct cells – *Pdx1* is again found at the top of the genetic cascade that triggers this regeneration process [55, 56].

Among the DNA sequences recognized by *Pdx1* protein, one easily recognizes the core sequence TAAT, a typical target for homeodomain-containing proteins. Mutation of these TAAT motifs leads to a loss of *Pdx1* binding [36]. *Pdx1* is able to interact with numerous transcription and cofactors, such as *Hnf1*, *E47/Pan1*, *BETA2/NeuroD*, *Pbx1*, *Meis2*, *Prp1*, *p300* and *Pax6* [39, 46, 57–61] on the protein level. Because of their ability to create complexes with *Pdx1*, these proteins have the potential to influence the DNA-binding and transactivating properties of *Pdx1*. Some of these factors can create a huge variety of different protein complexes with or without *Pdx1*, so that *Pdx1* protein has to compete for contribution to distinct protein complexes [58, 61, 62].

Despite possible variations in the composition of *Pdx1*-containing DNA-binding complexes, the alignment of *Pdx1* targets uncovers striking similarities in their DNA sequences (fig. 2). Obviously acting in a feedback-loop regulation, *Pdx1*-containing complexes have been shown to recognize the following DNA sequences within the *Pdx1* promoter: 5'-GTCCTGCTAATAAACGACTTTT-3' (human, nt. -2779 to -2757) and 5'-ACACTT-TAATTGGTTTAC-3' (human, nt. -2748 to -2727) [37-39].

Regulation of a second transcription factor, *Nkx6.1*, implicates recognition of its promoter by *Pdx1* protein, which binds to the sequence 5'-CCCTCATAAGT-GATAATGATCTAGG-3' (mouse, nt. -812 to -788) [63]. In contrast to *Pdx1*, which itself remains active in mature β and δ cells throughout adulthood [35], the third known *Pdx1*-regulated transcription factor, paired-box gene *Pax4*, is only transiently expressed during development. *Pax4* is active in early pancreatic precursors and later in maturing β and δ cells. No *Pax4* protein is detectable in mature islet cells [21]. In the *Pax4* gene promoter *Pdx1* recognizes the *Pax4* A2-promoter motif 5'-TTTGAGT-TATGTATAATGTGAG-3' (human, nt. -1950 to -1926), and this motif is also bound by *Hnf1* protein [40]. In addition, this motif shows a high degree of similarity to DNA sequences within the promoter of the peptide IAPP produced in β and δ cells. In the IAPP promoter the according motif has been named A2/AT2 element [51, 64]: 5'-ACTGATGAGTTAATGTAATAATGACC-3' (human, nt. -163 to -138). The hormone IAPP is expressed similarly to the late expression pattern of *Pdx1* but in contrast to *Pax4*: the peptide is found in the adult in mature β and δ cells [65-68]. In fact, according to these observations, highly similar motifs recognizing the same factor (*Pdx1*) are present in different genes (*Pax4*,

IAPP) that are regulated oppositely within mature islet cells.

Besides the A2/AT2 element another motif within the IAPP promoter, the A1/AT3 motif (5'-GATGGAAAT-TAATGACAGAGG-3'; human, nt. -96 to -76) is bound by *Pdx1* [51, 64]. Another DNA sequence with striking similarity to A2/AT2 can be found within the *Pdx1* promoter (5'-CTGAGTTAATCAAATAAGT-3'; mouse, -818 to -800), but no functional study has been performed yet with this *Pdx1* promoter element. The same is true for further similar motifs appearing in *Nkx6.1*, *ngn3* and *Pax6* promoters [69; C. Brink and P. Gruss, unpublished].

Within the insulin promoter the so-called A3/A4-element [70] is recognized by *Pdx1* in rat [47]: 5'-GT-TAATAATCTAATTAC-3' (rat, nt. -224 to -207) and mouse [71] 5'-CTTATTAAGACTATAATAACCCTAA-GACTA-3' (mouse, nt. -220 to -191). These sequences show striking similarity to A2/AT2 as well as the *Pdx1*-binding GLUT2TAAT element [52] of the GLUT2 promoter: 5'-TGACTTAATAATAACAGTA-3' (human/mouse, nt. -517 to -488). Further interactions have been demonstrated between *Pdx1* and the glucokinase promoter [54, 72] as well as the glucagon-promoter [73], using the promoter sequence 5'-GAACAAAACC-CCATTATT-TACAGATGAGAA-3' (mouse, nt. -103 to -74). Interestingly, using in vitro assays, it was also possible to show an interaction between *Pdx1* and the non- β -cell promoter of albumin [36]: 5'-TGAAGCTCAGGTTTAATTC-CCAGTCACAT-3' (mouse, nt. -336 to -308). In vivo, however, the interactions between *Pdx1* and insulin, IAPP, glucagon, *Pdx1* and *Pax4* promoters could be verified, whereas interactions with GLUT2, glucokinase or albumin promoters did not appear [36]. This suggests that chromatin structure has a decisive influence on promoter activity in these cases.

Sequence		Orientation	Promoter	
GC	TAATAAA	CGAC	→	h Pdx1
GT	TATGTAT	AATG	→	h Pax4
GT	TAATCAA	ATAA	→	m Pdx1*
TG	TAATAAT	GACC	→	h IAPP
CT	TAATAAT	AACA	→	h Glut2
GT	TAATAAT	CTAA	→	r Insulin
TA	TAATAAC	CCTA	→	m Insulin
GA	AATTAAT	GACA	→	h IAPP
CC	AATTAAT	GTGT	←	h Pdx1
GT	AAATAAT	GGGG	←	m Glucagon
GA	TAATGAT	CTAG	→	m Nkx6.1

Figure 2. *Pdx1* target sequences. Aligning the DNA sequences that are recognized by *Pdx1* protein reveals a predominance for binding to 5'-TAATAAT-3' (box). Arrows indicate the orientation of the given sequence within the given promoter. The sequence out of the *Pdx1* promoter that is marked with an asterisk is listed because of its similarity to the other *Pdx1*-targets, but no binding of the protein has yet been shown for this element.

Exocrine or endocrine:
Hnf6, *ngn3* and *NeuroD/BETA2*

Early in development the decision between exocrine and endocrine cell fate marks a first bifurcation in the course of pancreas development after induction [74, 75]. There is evidence that onecut-homeodomain transcription factor *Hnf6* [12], the basic helix-loop-helix transcription factors *ngn3* [18] and *NeuroD/BETA2* [19], and also the paired-box transcription factor *Pax6* [20] participate in controlling the switch between endocrine and exocrine tissue [27]. An influence of a *notch-hes1*-mediated mechanism of mutual fate inhibition (fig. 3, red arrows) has been discussed [27, 76].

Except for *Hnf6*, all of these factors are specifically active within endocrine cells. For all of them loss-of-function-analysis was performed, and without exception the phenotypes solely affect endocrine cell types, leaving the




Figure 3. Genetic interactions of pancreatic genes after induction. An overview of the currently known genetic interactions of genes important for development and function of the endocrine pancreas is given. Red arrows mark the genetic network that has been discussed to mediate the decision between exocrine and endocrine cell fate [26]. For *Hnf1α* and *Hnf4α* only the pancreatic regulation pathway is shown; in hepatic tissue the regulation hierarchy between these two factors is inverted [17].

exocrine solely affect normal. On the other hand, *P48* [25, 26] and *Mist1* [24] represent factors which particularly influence exocrine tissue development. Two exocrine cell types can be found: acinar and duct cells [77, 78]. Interestingly, the decision between exocrine and endocrine fate is not necessarily final. At least for regenerative processes, the duct cells seem to represent a link between exocrine and endocrine cell fate [56, 79]. In the following sections, however, this review will focus solely on the endocrine factors. The most important currently known interactions between endocrine genes are summarized in figure 3.

Even though early *Hnf6* activity is visible in epithelial cells that give rise to exocrine as well as to endocrine tissue and later disappears from the islets [80, 81], the loss-of-function phenotype of the gene exclusively shows effects that are restricted to the endocrine part of the organ [12]. Animals missing both functional *Hnf6* alleles lack complete Islets of Langerhans at birth, and at this developmental stage only a few endocrine cells are found. Later, however, perturbed islets may appear, but still the grown-up mice remain diabetic. Interestingly, downregulation of the gene at birth in endocrine cells is also necessary for proper islet formation and function [82]: persistent *Hnf6* expression in islets leads to diabetic mice with disturbed islet architecture and nonfunctional β cells.

Hnf6 is regulated by the interplay between growth hormone (GH), *Hnf4α* and C/EBP activity [83, 84]. The mechanism by which *Hnf6* is turned off in mature islets, however, is still unknown.

Currently known downstream targets of *Hnf6* are numerous liver-expressed genes [85] and the pancreatic factors

Foxa2, *Hnf4* and *ngn3* [12, 79, 86]. Competition between *Foxa2* and *Hnf6* for binding the same target sequences has been discussed [85]. There are two isoforms of *Hnf6*, α and β , which are both capable of binding as a monomer as well as integrated into complexes [86]. The p300/CREB binding protein-associated factor (p/CAF) is – among others – one possible partner of *Hnf6* in DNA binding [87].

For binding of *Hnf6* the DNA motif 5'-ATNGA-3' turns out to be most crucial (fig. 4). Out of the *Hnf6*-regulated hepatic genes the consensus binding motif 5'-TTATT GATTT-3' emerged [85, 86], which is highly consistent with the motifs recognized by *Hnf6* during pancreas development: the *Foxa2* promoter (5'-CGATATTGATTTTT-3'; rat, nt. -139 to -126) and the inverted *Hnf4α* promoter element (5'-AAGTCAATGA-3', nt. -387 to -378) [84]. It is also similar to inverted *Hnf6*-bound sequences of the *ngn3* promoter (5'-AAATC-CATGT-3'; mouse, nt. -3187 to -3178 and 5'-GCATC-CATAG-3'; mouse, nt. -453 to -444) [12]. A summary of the *Hnf6*-bound DNA motifs is depicted and discussed in figure 4.

Out of all *Hnf6*-regulated genes, *ngn3* seems to represent the most important factor lining up the main switch for enabling islet development – comparable to the role of *Pdx1* at the beginning of pancreas development [88]. Like *Pdx1*, *Ngn3* is capable of inducing endodermal outbudding upon ectopic endodermal expression. Within these buds, *ngn3* mediates the differentiation of endocrine cells that form islet structures, whereas ectopic *Pdx1* induces an – at least partial – pancreatic cytodifferentiation [88]. This observation is evident since it has been shown that *ngn3*-expressing cells are islet progenitors, whereas pancreas progenitors are marked by *Pdx1* expression [89]. Without *ngn3* activity, no endocrine cell types are present [18]. Besides *Hnf6*, the factors *Hnf1α* and *Foxa2* as well as the notch-regulated *Hes1* bind to the *ngn3* promoter and influence its expression rate [90].

As a member of the *bHLH* family of transcription factors *ngn3* directly influences the expression of another islet specific *bHLH* gene, *NeuroD/BETA2* [29]. A loss of function assay of *NeuroD/BETA2* implicates a phenotype similar to, but less severe than, *ngn3*, leading to a diminished number of all endocrine cell types [19].

<u>Sequence</u>	<u>Orientation</u>	<u>Promoter</u>
TTATTGATTT	→	Consensus liver
ATATTGATTT	→	r <i>Foxa2</i>
TCATTGACTT	←	<i>Hnf4α</i>
CTATGGATGC	←	m <i>ngn3</i> prox
ACATGGATTT	←	m <i>ngn3</i> dist

Figure 4. *Hnf6* target sequences. The *Hnf6* target sequences and their orientation in the particular promoter are given. The core sequence 5'-ATNGA-3' emerges from all *Hnf6*-bound motifs.

Both *bHLH* factors, *ngn3* as well as *NeuroD/BETA2*, have been shown to contribute to protein complexes which regulate the β - and δ -cell-specific transcription factor *Pax4* [40] and the insulin gene [91–94] by binding the so-called E1 motif [70], an E-box sequence within the gene promoters [41, 70]. Like the A2 motif, the E1 element is a cis-regulatory element which in the pancreas plays an important role in the transcriptional control of two diverse genes: *Pax4* as a developmental control gene and the peptide hormone insulin. The E1 elements of both promoters are related not only in their structure but also in biochemical function concerning the binding of protein complexes [40, 41]. Besides the *Pax4* promoter, the E1-type E-box motif can be also found and features striking identities in every investigated insulin promoter so far [70]. Interestingly, the sequence found within the *Pax4* gene promoter [41] (5'-AGCAGATGGC-3'; mouse, nt. -1950 to -1941) appears to be inverted in comparison to the motif of the insulin promoter [95, 96] (5'-GC-CATCTGCT-3'; rat, nt. -100 to -91). E1 elements of other insulin (insulin I) genes are [70, 97–99]: 5'-GC-CATCTGCC-3' (mouse, nt. -106 to -97), 5'-GCCATCTGCC-3' (rat, nt. -112 to -103) and 5'-GCCATCTGCC-3' (human, nt. -111 to -102). The core sequence CATCTG representing the E-box motif (CANNTG) [30, 100] further shows up within the glucagon promoter [96, 101]. E-box motifs in general are present in many other pancreatic promoters [102–105] – among others in *Pdx1* [106] – and are mostly recognized by *NeuroD/BETA2* [30, 107] or by other *bHLH* proteins, for example *ngn3* [29, 40].

Binding of a substantial protein complex could be demonstrated by performing investigations upon the E1 element of the insulin promoter [108, 109]. Within this complex *NeuroD/BETA2* – or *ngn3* – in combination with the *E2A* gene products E47, E12 and E2/5, and *HEB* gene products, bind to the insulin-E1 sequence [110]. Even though these ubiquitously expressed cofactors are not necessary for the interaction between *NeuroD/BETA2* and E1 element [111, 112], this protein machinery-influencing polymerase II activity seems to be conserved among several regulatory processes on the biochemical level [93, 113]. The effect of the *NeuroD/BETA2* complex on polymerase II activity by binding to the E1 sequence has the potential to be positively as well as negatively influenced by factors such as *p300* [93] and *c-jun* or adenovirus E1A [114–116], respectively. These observations point up the regulatory potential of the *NeuroD/BETA2*:*E47* protein complex. Moreover, recently supplied evidence for an interaction between the E1-binding complex and the *Pdx1* protein, which binds the neighboring A3/4 motif, of the insulin promoter throws light on a complex regulation mechanism, at least for insulin expression [61]. A scheme for possibly according interactions between the proteins acting on the neighboring A2 and E1 elements of the *Pax4* promoter is shown in figure




Figure 5. Scheme of protein complexes binding and potentially interacting on the A2 and E1 elements in the *Pax4* promoter. Within the insulin promoter an interaction between the E2-element binding protein complex (*NeuroD*: E47) and A3/4 element-bound *Pdx1* has been demonstrated [58]. Within the *Pax4* promoter *Pdx1* and *Hnf1α* have been shown to recognize the A2 element, and *NeuroD* was identified as a member of the neighboring E1-element-binding protein complex [37]. The *p300* coactivator was shown to mediate an interaction between both complexes. These observations suggest a similar interaction takes place within the *Pax4* promoter.

5. The inhibiting activity of adenovirus E1A is mainly based upon the disturbance of the interaction between *p300* and *Pdx1* [61].

Taken together, three observations make it tempting to speculate that in this case identical biochemical mechanisms might be the basis of oppositional effects: First, in contrast to *Pax4*, insulin is expressed in mature β cells after birth. Second, both genes contain adjacent E1- and *Pdx1*-binding A2 elements in their promoters. Third, in comparison with the insulin promoter the E1 element of the *Pax4* promoter is inverted [41].

Winged-helix transcription factors

Many genes originally described as hepatocyte nuclear factors (*Hnf* genes) also play a role in endocrine pancreas development and function [117, 118]. Whereas the *Hnf6* gene is characterized by a bifunctional onecut-type homeodomain [12, 28], other members of the *Hnf* gene family, *Hnf3α*, *Hnf3β* and *Hnf3γ*, belong to the winged-helix class of transcription factors [119–121]. Therefore they have been renamed *Foxa1*, *Foxa2* and *Foxa3*, respectively [122]. *Foxa1* is important for α -cell function [13]. It has been shown to recognize and regulate the glucagon promoter by binding the G2 element (5'-AGGCACAA-GAGTAAATAAAAAG-TTCCGGCCTCTG-3'; rat, nt. -200 to -164) [123]. *Foxa2*, on the other hand, plays an important role in early endoderm development [124], and its malfunction could be linked to pancreatic disorders [125]. Because of a severe phenotype that leads to early

lethality, insight into the role of *Foxa2* in pancreas development and function emanates from conditional gene-targeting experiments. The factor appears to be necessary for β cell function [126]. *Foxa2* interacts with the *Pdx1* promoter [36, 104, 127–130] at sequences 5'-CCGTTTTTGTATTATTTATCCA-3' (mouse, nt. –2713 to –2693), 5'-CTTTTTTGTATTATTTATCCATA-3' (human, nt. –2727 to –2706), 5'-GTGCTAAGCAAACATCCT-3' (mouse, nt. –2013 to –1996), 5'-AGTGCAAAGTAAACACTCCGG-3' (human, nt. –2102 to –2122) and 5'-GAACAGAAAGTAAATAAGCGC-3' (mouse, nt. –5927 to –5907); 5'-GGTATTTATTTATATATATATATATAT-3' (human, nt. –3591 to –3565). In the *ngn3* promoter [90] *Foxa2* binds to 5'-TTATTATTATTTTAGCAAACTACTGGAGACAG-3' (human, nt. –3699 to –3669) and 5'-GATCTCTCGAGAGAGCAAACAGCGCGGCGG-3' (human, nt. –200 to –170). Also, an interaction with the promoter of the exocrine factor amylase has been described at recognition site 5'-CTGTACCTTAAATATTTACTCATGAGCATTTA-3' (mouse, nt. –89 to –58) [131]. In general, the consensus recognition sequence 5'-(G/A/C)A(T/A)T(A/G)TT(T/G)(A/G)(T/C)T(T/C)AGTC-3' emerged, to which *Foxa2* binds as a monomer [132–134]. An alignment of *Foxa2* binding sites is depicted in figure 6.

Foxa1 and *Foxa3* bind to the same or similar sequences. The glucagon G2 element, for example, is a target of both genes [135]. The current results suggest that *Foxa3* does not play a role in the developing pancreas, but after birth a mild phenotype appears upon gene targeting: mature islets of loss of function mice show defective functions which are due to the missing regulation of *Glut2* by *Foxa3* in differentiated cells [136].

	Sequence	Orientation	Promoter
T	TGACTTAGT		cris.
AAT	TGTTTATTT		cons.
TTT	TGTTTATTT	ATCC →	m <i>Pdx1</i>
GAG	TGTTTACTT	TGCA ←	h <i>Pdx1</i>
GGA	TGTTTGCTT	AGCA ←	m <i>Pdx1</i>
CGC	TGTTTGCTC	TCTC ←	h <i>ngn3</i>
CAG	TGTTTGCTA	AAAT ←	h <i>ngn3</i>
GCT	TATTTACTT	TCTG ←	m <i>Pdx1</i>
AAA	TATTTACTC	ATGA →	m amylase
TTT	TATTTACTC	TTGT ←	r glucagon G2
GGG	TATTTATTT	ATAT →	h <i>Pdx1</i>
AAA	TATTTAAGG	TACA ←	m amylase

Figure 6. *Foxa2* target sequences. An alignment of the *Foxa2*-recognized DNA sequences within pancreatic promoters shows similarities with the consensus of the *Foxa2*-bound motifs of hepatic genes (cons.). Surprisingly, crystallographic analysis has led to identification of a highly divergent DNA sequence serving as *Foxa2* target (cris.). Sequences and orientation within the promoters are given, respectively. Highest conservation can be found for the core sequence 5'-TGTTTNNNT-3'.

Hnf1 and *Hnf4*

The transcription factors *Hnf1 α* , *Hnf1 β* and *Hnf4 α* play essential roles in pancreas development and function [137–140]. *Hnf1 α* , like the related gene *Hnf1 β* , contains a homeodomain-like DANN binding domain [141–143]. No functional role for *Hnf1 β* in pancreas development has yet been reported [144–146], but malfunction of the gene was linked to pancreatic disorders [147–152]. Further, a pancreatic tissue-specific effect on the P2 promoter of the *Hnf4 α* gene could be demonstrated [153]. *Hnf1 β* recognizes the same target sites as *Hnf1 α* , and they bind DNA as homo- or heterodimers [154, 155], for example during recognition of the P2 element of the *Hnf4 α* gene and during regulation of the insulin A3 element [156].

Especially interesting is the regulation of the P2 promoter element 5'-AGTGACTGGTTACTCTTTAACGTATCAC-3' (human, nt. –93 to –65) [17], since it drives the expression of an islet-specific splice variant of *Hnf4 α* in differentiated islet cells [17, 153]. This process inverts the regulation pathway that has been described during liver development, where *Hnf1 α* lies downstream of *Hnf4 α* [157–159].

An important role for *Hnf1 α* itself during pancreas development directly emerged from several loss-of-function studies [160–169]. Accordingly, the interactions between *Hnf1 α* and several promoters mediating pancreatic gene activity have been described, and effects on the transcriptional control of *Foxa3* (5'-TGTTAATAGTTAAC-3'; mouse, +16 kb) [170], *Hnf4 α* and the factors *glut2* and *pklr* by *Hnf1 α* were shown [17]. Further *Hnf1 α* target sequences exist within the *Pdx1* gene, where the previously described *Foxa2* target [130] and the sequence 5'-GTCCTGCTAATAACGACTTTTT-3' (human, nt. –2763 to –2741) [37] are recognized. As mentioned, together with *Hnf1 β* the A3 element of the insulin promoter at 5'-TGTTAAGACTCTAATGACC-3' (human, nt. –231 to –211) [156, 171] can be bound by *Hnf1 α* . In the *ngn3* promoter the target sequence 5'-CTTGTAATTATTTAT-TAAACGAAATCT-3' (human, nt. –3728 to –3702) [90] and in the *Pax4* promoter the target 5'-TTGAGTTAATG-TATAATTGTGAGCA-3' (human, nt. –1950 to –1926) [40] are recognized. The favored liver-specific *Hnf1 α* recognition sequence consensus is GGTTAATNAT-TANCA [172, 173], which shows high identity to the pancreas-specific sites. In general, there seem to exist two recognition sequences that can be used by *Hnf1 α* as DNA targets. The first represents the partial palindrome 5'-GGTTANNNTTANC-3'; the second deviates from this consensus to preferentially recognize 5'-TTAATAAATA-3'. Alignment of the *Hnf1 α* recognition sequences is shown and discussed in figure 7. Still, *Hnf1 α* has the potential to contribute to the regulation of many more pancreatic genes [174]. This potential may include the in-

Sequence		Orientation	Promoter
GG TTAA	TNA	→	cons. liver
GG TTAA	CTA	←	m Foxa3
GG TTAC	TCT	→	h Hnf4 (P2)
GG	TTAA GAC TCT	→	h insulin (A3)
AG	TTAA TGT ATA	→	h Pax4
GT	TTAA TAA ATA	←	h ngn3
TA	TAAA TAA ATA	←	h Pdx1
TG	CTAA TAA ACG	→	h Pdx1

Figure 7. *Hnf1α* target sequences. The currently described *Hnf1α* target DNA sequences are aligned, and the corresponding orientation in the according promoter is given. Two motifs emerge from this alignment: First, the incomplete palindrome 5'-GGTTAANNNT-TANC-3' emerges. Second, a consensus sequence similar to the motif 5'-TTAATAAATA-3' can be recognized within another group of *Hnf1α* targets. Tissue-specific regulation of the P2 promoter element within the *Hnf4* promoter shows that these two target motifs are not representing tissue-specific promoter elements, since the pancreas-specific P2 promoter uses the palindrome target sequence, which is highly similar to the consensus sequence recognized by *Hnf1α* protein in liver tissue (cons. liver).

involvement of further cofactors like it has been shown for p300 on the *Glut2* promoter (nt. +200 to +218) [175]. The *Hnf4*-genes are members of the nuclear hormone receptor superfamily and contain a zinc-finger DNA binding motif [176]. Several isoforms of *Hnf4* represent related genes (*Hnf4α*, *β*, *γ*), but splice variants have also been described [177, 178]. *Hnf4β* and *Hnf4γ* turned out to recognize *Hnf4α*-binding DNA motifs and have been shown to exhibit an expression pattern similar to the previously detected *Hnf4α* [118, 140, 179, 180]. *Hnf4α*-to-DNA binding occurs exclusively as homodimers [181, 182], is phosphorylation dependent [183] and can be influenced by coactivators [184]. *Hnf4α* is involved in numerous developmental and regulatory processes: loss-of-function studies revealed its important role in its expression domain, the visceral ectoderm, in early development [185–187]. *Hnf4α* is further present in mature pancreatic islets [188] and is necessary for islet function [189–191]. From the sites recognized by *Hnf4α* in hepatic genes, the preferred consensus 5'-GGGCCAAAGGTCA-3' emerged

Sequence		Orientation	Promoter
GGG	CCAAAGG	→	cons. liver
AGT	CCAAAGT	→	h Hnf1α
GGG	CCAAACG	→	r insulin
AAC	TCAAAGG	←	h Pax4

Figure 8. *Hnf4α* target sequences. Alignment of *Hnf4α* target DNA sequences shows the similarity between motifs within hepatic and pancreatic genes (box). The sequence and orientation within the given promoter are indicated. The core sequence 5'-CAAA-3' is consistent within all *Hnf4α*-bound motifs.

[192], which is mirrored, for example in the binding site of the *Hnf1α* promoter: 5'-AGTCCAAAGTTCA-3' (human, nt. -66 to -48) [193]. *Hnf4α* influences the expression rate of several pancreatic genes [194]. A direct interaction between *Hnf4α* and cis-regulatory elements of pancreatic promoters could be shown for the *Pax4* promoter (5'-GTGGCAAGACCTTTGAGTTAA-3'; human, nt. -1960 to -1940) [40] and for the insulin promoter (5'-GCCCTTAATGGGCCAAACGGCAAAGTCCAGG-3'; rat, nt. -84 to -54) [195]. The *Hnf4α* target DNA sequences are assembled and discussed in figure 8.

Pax transcription factors

Two members of the *Pax* family of transcription factors, *Pax4* and *Pax6*, have been shown to be crucial for cell identity and islet architecture within the endocrine pancreas [196–198] and for gastrointestinal endocrine cell development [199]. Without *Pax4* no *β* cells, in a *Pax6* loss-of-function animal no *α* cells and no islet structures form within the organ, and the total number of endocrine cells is reduced [20, 21, 200]. Several splice variants of *Pax4* have been described that might achieve oppositional effects, respectively [201, 202]. However, *Pax4* was shown to act as a transcriptional repressor gene [203–206], possibly binding to and competing for the same motifs as *Pax6* [207]. By affinity selection to random oligonucleotides the bipartite recognition sequence 5'-AAAATTA-N15-(C/T)CACCCC-3' emerged, and similar motifs in hormone gene regulatory elements are bound by *Pax4* protein [203]. *Pax4* has been shown to bind the sequences 5'-GCCAGACCTGTCCCTGCTCACAGCT-3' (human, nt. -262 to -238) in the insulin and to possibly act on 5'-ACTTTCTATCTATAGGGATG-3' (human, nt. -111 to -92) in the IAPP promoter [205, 64]. In another study the binding motif 5'-GCANTCANGCGTGAA-3' for the *Pax4* and other paired domains and the palindrome 5'-TAAT-N₁₋₅-ATTA-3' for the *Pax4* and other homeodomains have been described [208]. For *Pax6* several binding sequences emerged that show similarities to the *Pax4* binding sites. Three different studies describe *Pax6*-binding sequences, that have been selected by their affinity for *Pax6* protein: T5'-ANNTTCACGC(A/T)T(G/C)ANT(G/T)(A/C)NT-3' [209], 5'-(G/A)NG(C/A)ANT(G/C)A(A/T)GCGT(G/A)AA-3' [210] and 5'-TTAGT-TCCAG GTCAG-3' (present in a human soluble guanylate cyclase large subunit intron) [211]. *Pax6* was further shown to directly bind the *Pdx1* promoter (5'-AATAAATGAAGCGTCGAGAT-3'; mouse, nt. -2071 to -2052) [127]. On the G1 element (5'-CCCCATTATTTACAGATGAGAAATTTATATTGTCAGCGTAATATCTGCAAGGCTAAACAG-3'; rat, nt. -94 to -34) of the glucagon promoter *Pax6* builds a complex with *Cdx2*-, *MafA*- and *p300*- protein [211–215]. The glucagon

Sequence	Orientation	Promoter
TTCACGC	N	TGA
TTCACGC	T	TCA
TTCACGC	A	TGA
TTCACGC	C	TGA
TTTACAG	A	TGA
		G
		AAA

Figure 9. Target DNA sequences of *Pax4* and *Pax6*. Target sequences for *Pax4* and *Pax6* have been described based on their ability to bind protein as random PCR (polymerase chain reaction) fragments. Additionally, the glucagon promoter sequences G1 and G3 have been described as *Pax6* targets and fit to the consensus sequences of these findings. However, in the alignment depicted, only the most similar outcome of investigations upon *Pax*-targets is shown. Further potential targets can be found, some of them showing a bipartite consensus. Details about these motifs can be found in the text.

G3 element (5'-TTTTTCACGCCTGACTGAGATTG-AAGGGTGTA-3'; rat, nt. -265 to -240) contains a sequence motif that is responsible for islet-cell-specific expression of insulin, glucagon and IAPP (5'-CGCCTGA-3'), and is also recognized by *Pax6* [216–218]. The similarity of the particular sequences is given as an alignment in figure 9.

A third *Pax* gene, *Pax2*, might also contribute to pancreas development. However, no functional analysis of *Pax2* in the pancreas has been performed yet, but it has been shown to be expressed in pancreatic islets and to transactivate glucagon. It binds the glucagon G1 element with lower and the G3 element with higher affinity than *Pax6* [219]. A screen for *Pax2* targets additionally revealed the recognition motifs 5'-GNNTTAANT-CAAGTGANACAGTT-3' [220], 5'-TCA(T/C)GC(A/G)-TGACNA-3' [221] and for the paired domain 5'-(G/C)AAAC(T/A)C-3' [222].

Nk transcription factors

Nkx2.2 and *Nkx6.1* have been demonstrated to have decisive influence on maturation of pancreatic islet cells [22, 23, 223]. They both belong to the NK type of homeobox genes [224]. *Nkx2.2* directly regulates *Nkx6.1* [23, 225]. In the *Nkx6.1* promoter *Nkx2.2* recognizes the sequences 5'-CCCTCATAAGTGATAATGATCTAGG-3' (mouse, nt. -812 to -788) in parallel to *Pdx1* and is also able to recognize 5'-CGGAAGAGACGCACTTAAACT-GCTTTTC-3' (mouse, nt. -478 to -441) [63]. *Nkx6.1* acts as a repressor on the insulin promoter and recognizes the sequence 5'-TTAATTAC-3', (5'-AATCTAATTACCCT-3'; rat insulin A3/A4-element), but the COOH terminus inhibits this interaction [63, 226].

Hlxb9, *Isl1*, *Cdx2* and *MafA*

The homeobox gene *Hlxb9* has been shown to play an important role in pancreas development and function, mainly according to the dorsal part of the organ [227–230]. Despite this fact no search for *Hlxb9* target sequences has yet been performed.

Developmental function of the LIM-domain homeobox transcription factor *Isl1* affects the pancreas and the surrounding mesenchyme [231], and it also plays a role for islet function [232]. It has been shown to bind the insulin promoter at 5'-TTAATAATCTAATTA-3' (rat, nt. -222 to -208) [233]. The somatostatin promoter is recognized at 5'-TTGCGAGGCTAATGGTG-3' (rat, nt. -104 to -88) [234, 235]. *Isl1* binds the IAPP promoter at 5'-GAGT-TAATGTAATAATGACC-3' (human, nt. -156 to -137) [236] and the glucagon promoter at several sites within the G1 element (see above) [237].

Cdx2, one of three caudal homologues in vertebrates, plays an important role in early development and is regulated by *Oct1* [238–242]. In endocrine cells it has been shown to autoregulate itself by using the sequences 5'-GTAAACACTCGTTAATCACGTAAGGC-3' (mouse, nt. -18 to +18) and 5'-TGTGTCATTACTAATA-GAGTCTTGTA-3' (mouse, nt. -41 to -16) [243]. *Cdx2* activates glucagon expression by interaction with *Pax6* and p300 on the G1 element (see above), where the motifs 5'-TAAATATAA-3' and 5'-ATTATA-3' are crucial [244–248]. Further recognition of *Cdx2* has been demonstrated for the insulin promoter (5'-TGTTAATAATC-TAATTA-3'; rat, see above) [249], as for many more AT-rich elements in various promoters, such as 5'-AATAAACTTTAT-3' [241], 5'-TATTTTA-3' [250], 5'-TATTTTACAA-3' [251], 5'-TAAAGACTATAAAA-3' [252, 253], 5'-TTTTAT-3', 5'-TAATTGTTTTATGGTT-TAA-3' [254] and more [255–258], with one example including an interaction with *Hnf1α* [259].

The basic leucine zipper gene *MafA*, known as a phosphorylation-dependent downstream target of *Pax6* in lens development, has recently been shown to bind the insulin promoter RIPE3b1 element at 5'-TGGAAACT-GCAGCTTCAGCCCCTCTG-3' (human, nt. -126 to -101) [260–262].

Conclusion

The development of the endocrine pancreas is an important and growing field of research. Learning about the genetic program that underlies the differentiation, regeneration and function of distinct endocrine cell types will enhance our potential to cure hormonal diseases arising from pancreatic disorders.

This review summarizes the currently known cis-regulatory DNA sequences and the transcription factors and pro-

tein complexes that play a role in endocrine cell differentiation and function. Apparently, in numerous cases the motifs recognized by a certain protein or protein complex in different promoters feature striking similarities. Such sequences might serve as templates for screening further pancreatic promoters, helping to achieve initial hints about possible regulatory elements. Large motifs that are highly consistent might even be used for screening large genomic sequences or even genomes for pancreatic factors: since several genomes have been sequenced, 'reverse genetics' have become a potent tool of life science. A combinatory screen 'in silico' for open reading frames and certain neighboring cis-regulatory elements will be a future way of identifying new genes and their field of activity before even knowing their biochemical identity. But the biochemical mechanisms of many transcription factors and protein complexes influencing transcription still need to be elucidated and will lead to the detection of even more genes influencing pancreas development.

- 1 Huang H. P. and Tsai M. J. (2000) Transcription factors involved in pancreatic islet development. *J. Biomed. Sci.* **7**: 27–34
- 2 Yamaoka T., Itakura M. (1999) Development of pancreatic islets. *Int. J. Mol. Med.* **3**: 247–261
- 3 Edlund H. (2002) Pancreatic organogenesis—developmental mechanisms and implications for therapy. *Nat. Rev. Genet.* **3**: 524–532
- 4 Kim S. K., Hebrok M., Melton D. A. (1997) Notochord to endoderm signaling is required for pancreas development. *Development* **124**: 4243–4252
- 5 Yamaoka T., Idehara C., Yano M., Matsushita T., Yamada T., Ii S. et al. (1998) Hypoplasia of pancreatic islets in transgenic mice expressing activin receptor mutants. *J. Clin. Invest.* **102**: 294–301
- 6 Hebrok M., Kim S. K., Melton D. A. (1998) Notochord repression of endodermal Sonic hedgehog permits pancreas development. *Genes Dev.* **12**: 1705–1713
- 7 Roy S., Qiao T., Wolff C., Ingham P. W. (2001) Hedgehog signaling pathway is essential for pancreas specification in the zebrafish embryo. *Curr. Biol.* **11**: 1358–1363
- 8 Jonsson J., Carlsson L., Edlund T., Edlund H. (1994) Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* **371**: 606–609
- 9 Offield M. F., Jetton T. L., Labosky P. A., Ray M., Stein R. W., Magnuson M. A. et al. (1996) PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* **122**: 983–995
- 10 Li H., S., Jessell T. M., Edlund H. (1999) Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlx9. *Nat. Genet.* **23**: 67–70
- 11 Harrison K. A., Thaler J., Pfaff S. L., Gu H., Kehl J. H. (1999) Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlx9-deficient mice. *Nat. Genet.* **23**: 71–75
- 12 Jacquemin P., Durvieux S. M., Jensen J., Godfraind C., Gradwohl G., Guillemot F. et al. (2000) Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene *ngn3*. *Mol. Cell. Biol.* **20**: 4445–4454
- 13 Kaestner K. H., Katz J., Liu Y., Drucker D. J., Schutz G. (1999) Inactivation of the winged helix transcription factor HNF3 α affects glucose homeostasis and islet glucagon gene expression in vivo. *Genes Dev.* **13**: 495–504
- 14 Shih D. Q., Navas M. A., Kuwajima S., Duncan S. A., Stoffel M. (1999) Impaired glucose homeostasis and neonatal mortality in hepatocyte nuclear factor 3 α -deficient mice. *Proc. Natl. Acad. Sci. USA* **96**: 10152–10157
- 15 Sund N. J., Vatamaniuk M. Z., Casey M., Ang S. L., Magnuson M. A., Stoffers D. A. (2001) Tissue-specific deletion of *Foxa2* in pancreatic beta cells results in hyperinsulinemic hypoglycemia. *Genes Dev.* **15**: 1706–1715
- 16 Dukes I. D., Sreenan S., Roe M. W., Levisetti M., Zhou Y. P., Ostrega D. et al. (1998) Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1 α -deficient mice. *J. Biol. Chem.* **273**: 24457–24464
- 17 Boj S. F., Parrizas M., Maestro M. A., Ferrer J. (2001) A transcription factor regulatory circuit in differentiated pancreatic cells. *Proc. Natl. Acad. Sci. USA* **98**: 14481–14486
- 18 Gradwohl G., Dierich A., LeMeur M., Guillemot F. (2000) *neurogenin3* is required for the development of the four endocrine cell lineages of the pancreas. *Proc. Natl. Acad. Sci. USA* **97**: 1607–1611
- 19 Naya F. J., Huang H. P., Qiu Y., Mutoh H., DeMayo F. J., Leiter A. B. et al. (1997) Diabetes, defective pancreatic morphogenesis and abnormal enteroendocrine differentiation in *BETA2/neuroD*-deficient mice. *Genes Dev.* **11**: 2323–2334
- 20 St-Onge L., Sosa-Pineda B., Chowdhury K., Mansouri A., Gruss P. (1997) *Pax6* is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. *Nature* **387**: 406–409
- 21 Sosa-Pineda B., Chowdhury K., Torres M., Oliver G., Gruss P. (1997) The *Pax4* gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. *Nature* **386**: 399–402
- 22 Sussel L., Kalamaras J., Hartigan-O'Connor D. J., Meneses J. J., Pedersen R. A., Rubenstein J. L. et al. (1998) Mice lacking the homeodomain transcription factor *Nkx2.2* have diabetes due to arrested differentiation of pancreatic beta cells. *Development* **125**: 2213–2221
- 23 Sander M., Sussel L., Connors J., Scheel D., Kalamaras J., Dela Cruz F. et al. (2000) Homeobox gene *Nkx6.1* lies downstream of *Nkx2.2* in the major pathway of beta-cell formation in the pancreas. *Development* **127**: 5533–5540
- 24 Pin C. L., Rukstalis J. M., Johnson C., Konieczny S. F. (2001) The bHLH transcription factor *Mist1* is required to maintain exocrine pancreas cell organization and acinar cell identity. *J. Cell. Biol.* **155**: 519–530
- 25 Krapp A., Knofler M., Ledermann B., Burki K., Berney C., Zoerkler N. et al. (1998) The bHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas. *Genes Dev.* **12**: 3752–3763
- 26 Kawaguchi Y., Cooper B., Gannon M., Ray M., MacDonald R. J., Wright C. V. (2002) The role of the transcriptional regulator *Ptf1a* in converting intestinal to pancreatic progenitors. *Nat. Genet.* **32**: 128–134.
- 27 Jensen J., Heller R. S., Funder-Nielsen T., Pedersen E. E., Lindsell C., Weinmaster G. et al. (2000) Independent development of pancreatic alpha- and beta-cells from *neurogenin3*-expressing precursors: a role for the notch pathway in repression of premature differentiation. *Diabetes* **49**: 163–176
- 28 Lannoy V. J., Burglin T. R., Rousseau G. G., Lemaigre F. P. (1998) Isoforms of hepatocyte nuclear factor-6 differ in DNA-binding properties, contain a bifunctional homeodomain, and define the new ONECUT class of homeodomain proteins. *J. Biol. Chem.* **273**: 13552–13562
- 29 Huang H. P., Liu M., El-Hodiri H. M., Chu K., Jamrich M., Tsai M. J. (2000) Regulation of the pancreatic islet-specific gene *BETA2 (neuroD)* by *neurogenin 3*. *Mol. Cell. Biol.* **20**: 3292–3307
- 30 Naya F. J., Stellrecht C. M., Tsai M. J. (1995) Tissue-specific regulation of the insulin gene by a novel basic

- helix-loop-helix transcription factor. *Genes Dev.* **9**: 1009–1019
- 31 Walther C., Guenet J. L., Simon D., Deutsch U., Jostes B., Goulding M. D. et al. (1991) Pax: a murine multigene family of paired box-containing genes. *Genomics* **11**: 424–434
 - 32 Kim Y., Nirenberg M. (1989) Drosophila NK-homeobox genes. *Proc. Natl. Acad. Sci. USA* **86**: 7716–7720
 - 33 Gannon M., Herrera P. L., Wright C. V. (2000) Mosaic Cre-mediated recombination in pancreas using the pdx-1 enhancer/promoter. *Genesis* **26**: 143–144
 - 34 Gannon M., Shiota C., Postic C., Wright C. V., Magnuson M. (2000) Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. *Genesis* **26**: 139–142
 - 35 Hui H., Perfetti R. (2002) Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. *Eur. J. Endocrinol.* **146**: 129–141
 - 36 Chakrabarti S. K., James J. C., Mirmira R. G. (2002) Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. *J. Biol. Chem.* **277**: 13286–13293
 - 37 Gerrish K., Cissell M. A., Stein R. (2001) The role of hepatic nuclear factor 1 alpha and PDX-1 in transcriptional regulation of the pdx-1 gene. *J. Biol. Chem.* **276**: 47775–47784
 - 38 Marshak S., Benshushan E., Shoshkes M., Havin L., Cerasi E. et al. (2000) Functional conservation of regulatory elements in the pdx-1 gene: PDX-1 and hepatocyte nuclear factor 3beta transcription factors mediate beta-cell-specific expression. *Mol. Cell. Biol.* **20**: 7583–7590
 - 39 Gannon M., Gamer L. W., Wright C. V. (2001) Regulatory regions driving developmental and tissue-specific expression of the essential pancreatic gene pdx1. *Dev. Biol.* **238**: 185–201
 - 40 Smith S. B., Watada H., Scheel D. W., Mrejen C., German M. S. (2000) Autoregulation and maturity onset diabetes of the young transcription factors control the human PAX4 promoter. *J. Biol. Chem.* **275**: 36910–36919
 - 41 Brink C., Chowdhury K., Gruss P. (2001) Pax4 regulatory elements mediate beta cell specific expression in the pancreas. *Mech. Dev.* **100**: 37–43
 - 42 Peshavaria M., Gamer L., Henderson E., Teitelman G., Wright C. V., Stein R. (1994) X1Hbox 8, an endoderm-specific Xenopus homeodomain protein, is closely related to a mammalian insulin gene transcription factor. *Mol. Endocrinol.* **8**: 806–816
 - 43 Ohlsson H., Karlsson K., Edlund T. (1993) IPF1, a homeodomain-containing transactivator of the insulin gene. *EMBO J.* **12**: 4251–4259
 - 44 Ohneda K., Ee H., German M. (2000) Regulation of insulin gene transcription. *Semin. Cell. Dev. Biol.* **11**: 227–233
 - 45 Wang H., Maechler P., Ritz-Laser B., Hagenfeldt K. A., Ishihara H., Philippe J. et al. (2001) Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. *J. Biol. Chem.* **276**: 25279–25286
 - 46 Lottmann H., Vanselow J., Hessabi B., Walther R. (2001) The Tet-On system in transgenic mice: inhibition of the mouse pdx-1 gene activity by antisense RNA expression in pancreatic beta-cells. *J. Mol. Med.* **79**: 321–328
 - 47 Ohneda K., Mirmira R. G., Wang J., Johnson J. D., German M. S. (2000) The homeodomain of PDX-1 mediates multiple protein-protein interactions in the formation of a transcriptional activation complex on the insulin promoter. *Mol. Cell. Biol.* **20**: 900–91
 - 48 Peers B., Leonard J., Sharma S., Teitelman G., Montminy M. R. (1994) Insulin expression in pancreatic islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. *Mol. Endocrinol.* **8**: 1798–1806
 - 49 Ahlgren U., Jonsson J., Jonsson L., Simu K., Edlund H. (1998) beta-cell-specific inactivation of the mouse Ipfl/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. *Genes Dev.* **12**: 1763–1768
 - 50 Macfarlane W. M., Campbell S. C., Elrick L. J., Oates V., Bermano G., Lindley K. J. et al. (2000) Glucose regulates islet amyloid polypeptide gene transcription in a PDX1- and calcium-dependent manner. *J. Biol. Chem.* **275**: 15330–15335
 - 51 Watada H., Kajimoto Y., Kaneto H., Matsuoka T., Fujitani Y., Miyazaki J. et al. (1996) Involvement of the homeodomain-containing transcription factor PDX-1 in islet amyloid polypeptide gene transcription. *Biochem. Biophys. Res. Commun.* **229**: 746–751
 - 52 Waeber G., Thompson N., Nicod P., Bonny C. (1996) Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. *Mol. Endocrinol.* **10**: 1327–1334
 - 53 Watada H., Kajimoto Y., Miyagawa J., Hanafusa T., Hamaguchi K., Matsuoka T. et al. (1996) PDX-1 induces insulin and glucokinase gene expressions in alphaTC1 clone 6 cells in the presence of betacellulin. *Diabetes* **45**: 1826–1831
 - 54 Watada H., Kajimoto Y., Umayahara Y., Matsuoka T., Kaneto H., Fujitani Y. et al. (1996) The human glucokinase gene beta-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells. *Diabetes* **45**: 1478–1488
 - 55 Sharma A., Zangen D. H., Reitz P., Taneja M., Lissauer M. E., Miller C. P. et al. (1999) The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. *Diabetes* **48**: 507–513
 - 56 Kritzik M. R., Jones E., Chen Z., Krakowski M., Krahl T., Good A. et al. (1999) PDX-1 and Msx-2 expression in the regenerating and developing pancreas. *J. Endocrinol.* **163**: 523–530
 - 57 Liu Y., MacDonald R. J., Swift G. H. (2001) DNA binding and transcriptional activation by a PDX1.PBX1b.MEIS2b trimer and cooperation with a pancreas-specific basic helix-loop-helix complex. *J. Biol. Chem.* **276**: 17985–17993
 - 58 Goudet G., Delhalle S., Biemar F., Martial J. A., Peers B. (1999) Functional and cooperative interactions between the homeodomain PDX1, Pbx and Prep1 factors on the somatostatin promoter. *J. Biol. Chem.* **274**: 4067–4073
 - 59 Peers B., Sharma S., Johnson T., Kamps M., Montminy M. (1995) The pancreatic islet factor STF-1 binds cooperatively with Pbx to a regulatory element in the somatostatin promoter: importance of the FPWMK motif and of the homeodomain. *Mol. Cell. Biol.* **15**: 7091–7097
 - 60 Andersen F. G., Jensen J., Heller R. S., Petersen H. V., Larsson L. I., Madsen O. D. et al. (1999) Pax6 and Pdx1 form a functional complex on the rat somatostatin gene upstream enhancer. *FEBS Lett.* **445**: 315–320
 - 61 Qiu Y., Guo M., Huang S., Stein R. (2002) Insulin gene transcription is mediated by interactions between the p300 coactivator and PDX-1, BETA2 and E47. *Mol. Cell. Biol.* **22**: 412–420
 - 62 Shanmugam K., Green N. C., Rambaldi I., Saragovi H. U., Featherstone M. S. (1999) PBX and MEIS as non-DNA-binding partners in trimeric complexes with HOX proteins. *Mol. Cell. Biol.* **19**: 7577–7588
 - 63 Mirmira R. G., Watada H., German M. S. (2000) Beta-cell differentiation factor Nkx6.1 contains distinct DNA binding interference and transcriptional repression domains. *J. Biol. Chem.* **275**: 14743–14751
 - 64 Carty M. D., Lillquist J. S., Peshavaria M., Stein R., Soeller W. C. (1997) Identification of cis- and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells. *J. Biol. Chem.* **272**: 11986–11993
 - 65 Fehmann H. C., Weber V., Goke R., Goke B., Arnold R. (1990) Cosecretion of amylin and insulin from isolated rat pancreas. *FEBS Lett.* **262**: 279–281

- 66 Mulder H., Lindh A. C., Sundler F. (1993) Islet amyloid polypeptide gene expression in the endocrine pancreas of the rat: a combined in situ hybridization and immunocytochemical study. *Cell Tissue Res.* **274**: 467–474
- 67 Guz Y., Montminy M. R., Stein R., Leonard J., Gamer L. W., Wright C. V. et al. (1995) Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* **121**: 11–18
- 68 Sander M., German M. S. (1997) The beta cell transcription factors and development of the pancreas. *J Mol. Med.* **75**: 327–340
- 69 Reference removed in proof
- 70 German M., Ashcroft S., Docherty K., Edlund H., Edlund T., Goodison S. et al. (1995) The insulin gene promoter. A simplified nomenclature. *Diabetes* **44**: 1002–1004
- 71 Peshavaria M., Henderson E., Sharma A., Wright C. V., Stein R. (1997) Functional characterization of the transactivation properties of the PDX-1 homeodomain protein. *Mol. Cell Biol.* **17**: 3987–3996
- 72 Shelton K. D., Franklin A. J., Khor A., Beechem J., Magnuson M. A. (1992) Multiple elements in the upstream glucokinase promoter contribute to transcription in insulinoma cells. *Mol. Cell Biol.* **12**: 4578–4589
- 73 Morel C., Cordier-Bussat M., Philippe J. (1995) The upstream promoter element of the glucagon gene, G1, confers pancreatic alpha cell-specific expression. *J Biol. Chem.* **270**: 3046–3055
- 74 Herrera P. L. (2002) Defining the cell lineages of the islets of Langerhans using transgenic mice. *Int. J. Dev. Biol.* **46**: 97–103
- 75 Herrera P. L. (2000) Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. *Development* **127**: 2317–2322
- 76 Apelqvist A., Li H., Sommer L., Beatus P., Anderson D. J., Honjo T. et al. (1999) Notch signalling controls pancreatic cell differentiation. *Nature* **400**: 877–881
- 77 Kiehne K., Otte J. M., Folsch U. R., Herzig K. H. (2001) Growth factors in development and diseases of the exocrine pancreas. *Pancreatology* **1**: 15–23
- 78 Means A. L., Leach S. D. (2001) Lineage commitment and cellular differentiation in exocrine pancreas. *Pancreatology* **1**: 587–596
- 79 Kritzik M. R., Krahl T., Good A., Krakowski M., St-Onge L., Gruss P. et al. (2000) Transcription factor expression during pancreatic islet regeneration. *Mol. Cell. Endocrinol.* **164**: 99–107
- 80 Rausa F., Samadani U., Ye H., Lim L., Fletcher C. F., Jenkins N. A. et al. (1997) The cut-homeodomain transcriptional activator HNF-6 is coexpressed with its target gene HNF-3 beta in the developing murine liver and pancreas. *Dev. Biol.* **192**: 228–246
- 81 Landry C., Clotman F., Hioki T., Oda H., Picard J. J., Lemaigre F. P. et al. (1997) HNF-6 is expressed in endoderm derivatives and nervous system of the mouse embryo and participates to the cross-regulatory network of liver-enriched transcription factors. *Dev. Biol.* **192**: 247–257
- 82 Gannon M., Ray M. K., Van Zee K., Rausa F., Costa R. H., Wright C. V. (2000) Persistent expression of HNF6 in islet endocrine cells causes disrupted islet architecture and loss of beta cell function. *Development* **127**: 2883–2895
- 83 Rastegar M., Lemaigre F. P., Rousseau G. G. (2000) Control of gene expression by growth hormone in liver: key role of a network of transcription factors. *Mol. Cell. Endocrinol.* **164**: 1–4
- 84 Lahuna O., Fernandez L., Karlsson H., Maiter D., Lemaigre F. P., Rousseau G. G. et al. (1997) Expression of hepatocyte nuclear factor 6 in rat liver is sex-dependent and regulated by growth hormone. *Proc. Natl. Acad. Sci. USA* **94**: 12309–12313
- 85 Samadani U., Costa R. H. (1996) The transcriptional activator hepatocyte nuclear factor 6 regulates liver gene expression. *Mol. Cell Biol.* **16**: 6273–6284
- 86 Lannoy V. J., Burglin T. R., Rousseau G. G., Lemaigre F. P. (1998) Isoforms of hepatocyte nuclear factor-6 differ in DNA-binding properties, contain a bifunctional homeodomain, and define the new ONECUT class of homeodomain proteins. *J. Biol. Chem.* **273**: 13552–13562
- 87 Lannoy V. J., Rodolosse A., Pierreux C. E., Rousseau G. G., Lemaigre F. P. (2000) Transcriptional stimulation by hepatocyte nuclear factor-6. Target-specific recruitment of either CREB-binding protein (CBP) or p300/CBP-associated factor (p/CAF). *J. Biol. Chem.* **275**: 22098–22103
- 88 Grapin-Botton A., Majithia A. R., Melton D. A. (2001) Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. *Genes Dev.* **15**: 444–454
- 89 Gu G., Dubauskaite J., Melton D. A. (2002) Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* **29**: 2447–24457
- 90 Lee J. C., Smith S. B., Watada H., Lin J., Scheel D., Wang J. et al. (2001) Regulation of the pancreatic pro-endocrine gene neurogenin3. *Diabetes* **50**: 928–936
- 91 Whelan J., Cordle S. R., Henderson E., Weil P. A., Stein R. (1990) Identification of a pancreatic beta-cell insulin gene transcription factor that binds to and appears to activate cell-type-specific expression: its possible relationship to other cellular factors that bind to a common insulin gene sequence. *Mol. Cell Biol.* **10**: 1564–1572
- 92 Qiu Y., Sharma A., Stein R. (1998) p300 mediates transcriptional stimulation by the basic helix-loop-helix activators of the insulin gene. *Mol. Cell Biol.* **18**: 2957–2964
- 93 Sharma A., Moore M., Marcora E., Lee J. E., Qiu Y., Samaras S. et al. (1999) The NeuroD1/BETA2 sequences essential for insulin gene transcription colocalize with those necessary for neurogenesis and p300/CREB binding protein binding. *Mol. Cell Biol.* **19**: 704–713
- 94 Qiu Y., Guo M., Huang S., Stein R. (2002) Insulin gene transcription is mediated by interactions between the p300 coactivator and PDX-1, BETA2 and E47. *Mol. Cell Biol.* **22**: 412–420
- 95 Robinson G. L., Peshavaria M., Henderson E., Shieh S. Y., Tsai M. J., Teitelman G. et al. (1994) Expression of the trans-active factors that stimulate insulin control element-mediated activity appear to precede insulin gene transcription. *J. Biol. Chem.* **269**: 2452–2460
- 96 Cordier-Bussat M., Morel C., Philippe J. (1995) Homologous DNA sequences and cellular factors are implicated in the control of glucagon and insulin gene expression. *Mol. Cell Biol.* **15**: 3904–3916
- 97 Wentworth B. M., Schaefer I. M., Villa-Komaroff L., Chirgwin J. M. (1986) Characterization of the two nonallelic genes encoding mouse preproinsulin. *J. Mol. Evol.* **23**: 305–312
- 98 Lakshmikumaran M. S., D'Ambrosio E., Laimins L. A., Lin D. T., Furano A. V. (1985) Long interspersed repeated DNA (LINE) causes polymorphism at the rat insulin 1 locus. *Mol. Cell Biol.* **5**: 2197–2203
- 99 Owerbach D., Aagaard L. (1984) Analysis of a 1963-bp polymorphic region flanking the human insulin gene. *Gene* **32**: 475–479
- 100 Dumonteil E., Laser B., Constant I., Philippe J. (1998) Differential regulation of the glucagon and insulin I gene promoters by the basic helix-loop-helix transcription factors E47 and BETA2. *J. Biol. Chem.* **273**: 19945–19954
- 101 Steiner D. F., Chan S. J., Welsh J. M., Kwok S. C. (1985) Structure and evolution of the insulin gene. *Annu. Rev. Genet.* **19**: 463–484

- 102 Mutoh H., Ratineau C., Ray S., Leiter A. B. (2000) Review article: transcriptional events controlling the terminal differentiation of intestinal endocrine cells. *Aliment. Pharmacol. Ther.* **14 Suppl. 1**: 170–175
- 103 Mutoh H., Fung B. P., Naya F. J., Tsai M. J., Nishitani J., Leiter A. B. (1997) The basic helix-loop-helix transcription factor BETA2/NeuroD is expressed in mammalian enteroendocrine cells and activates secretin gene expression. *Proc. Natl. Acad. Sci. USA* **94**: 3560–3564
- 104 Poulin G., Turgeon B., Drouin J. (1997) NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. *Mol. Cell. Biol.* **17**: 6673–6682
- 105 Miyachi T., Maruyama H., Kitamura T., Nakamura S., Kawakami H. (1999) Structure and regulation of the human NeuroD (BETA2/BHF1) gene. *Brain Res. Mol. Brain Res.* **69**: 223–231
- 106 Sharma S., Jhala U. S., Johnson T., Ferreri K., Leonard J., Montminy M. (1997) Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene STF-1. *Mol. Cell. Biol.* **17**: 2598–2604
- 107 Murre C., McCaw P. S., Baltimore D. (1989) A new DNA binding and dimerization motif in immunoglobulin enhancer binding, Daughterless, MyoD and Myc proteins. *Cell.* **56**: 777–783
- 108 Cordle S. R., Henderson E., Masuoka H., Weil P. A., Stein R. (1991) Pancreatic beta-cell-type-specific transcription of the insulin gene is mediated by basic helix-loop-helix DNA-binding proteins. *Mol. Cell. Biol.* **11**: 1734–1738
- 109 Edlund H. (1998) Transcribing pancreas. *Diabetes* **47**: 1817–1823
- 110 Sharma A., Henderson E., Gamer L., Zhuang Y., Stein R. (1997) Analysis of the role of E2A-encoded proteins in insulin gene transcription. *Mol. Endocrinol.* **11**: 1608–1717
- 111 Melloul D., Marshak S., Cerasi E. (2002) Regulation of insulin gene transcription. *Diabetologia* **45**: 309–326
- 112 Itkin-Ansari P., Bain G., Beattie G. M., Murre C., Hayek A., Levine F. (1996) E2A gene products are not required for insulin gene expression. *Endocrinology* **137**: 3540–3543
- 113 Mutoh H., Naya F. J., Tsai M. J., Leiter A. B. (1998) The basic helix-loop-helix protein BETA2 interacts with p300 to coordinate differentiation of secretin-expressing enteroendocrine cells. *Genes Dev.* **12**: 820–830
- 114 Stein R. W., Whelan J. (1989) Insulin gene enhancer activity is inhibited by adenovirus 5 E1a gene products. *Mol. Cell. Biol.* **9**: 4531–4534
- 115 Robinson G. L., Henderson E., Massari M. E., Murre C., Stein R. (1995) c-jun inhibits insulin control element-mediated transcription by affecting the transactivation potential of the E2A gene products. *Mol. Cell. Biol.* **15**: 1398–1404
- 116 Henderson E., Stein R. (1994) c-jun inhibits transcriptional activation by the insulin enhancer, and the insulin control element is the target of control. *Mol. Cell. Biol.* **14**: 655–662
- 117 Shih D. Q., Stoffel M. (2001) Dissecting the transcriptional network of pancreatic islets during development and differentiation. *Proc. Natl. Acad. Sci. USA* **98**: 14189–14191
- 118 Vaisse C., Kim J., Espinosa R. 3rd, Le Beau M. M., Stoffel M. (1997) Pancreatic islet expression studies and polymorphic DNA markers in the genes encoding hepatocyte nuclear factor-3 alpha, -3 beta, -3 gamma, -4 gamma and -6. *Diabetes* **46**: 1364–1367
- 119 Costa R. H., Grayson D. R., Darnell J. E. Jr (1989) Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. *Mol. Cell. Biol.* **9**: 1415–1425
- 120 Lai E., Prezioso V. R., Tao W. F., Chen W. S., Darnell J. E. Jr (1991) Hepatocyte nuclear factor 3 alpha belongs to a gene family in mammals that is homologous to the *Drosophila* homeotic gene fork head. *Genes Dev.* **5**: 416–427
- 121 Clark K. L., Halay E. D., Lai E., Burley S. K. (1993) Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. *Nature* **364**: 412–420
- 122 Kaestner K. H., Knochel W., Martinez D. E. (2000) Unified nomenclature for the winged helix/forkhead transcription factors. *Genes Dev.* **14**: 142–146
- 123 Gauthier B. R., Schwitzgebel V. M., Zaiko M., Mamin A., Ritz-Laser B., Philippe J. (2002) Hepatic nuclear factor-3 (HNF-3 or Foxa2) regulates glucagon gene transcription by binding to the G1 and G2 promoter elements. *Mol. Endocrinol.* **16**: 170–183
- 124 Ang S. L., Rossant J. (1994) HNF-3 beta is essential for node and notochord formation in mouse development. *Cell* **78**: 561–574
- 125 Zhu Q., Yamagata K., Yu L., Tomura H., Yamada S., Yang Q. et al. (2000) Identification of missense mutations in the hepatocyte nuclear factor-3 beta gene in Japanese subjects with late-onset Type II diabetes mellitus. *Diabetologia* **43**: 1197–1200
- 126 Sund N. J., Vatamaniuk M. Z., Casey M., Ang S. L., Magnuson M. A., Stoffers D. A. et al. (2001) Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. *Genes Dev.* **15**: 1706–1715
- 127 Samaras S. E., Cissell M. A., Gerrish K., Wright C. V., Gannon M., Stein R. (2002) Conserved sequences in a tissue-specific regulatory region of the pdx-1 gene mediate transcription in Pancreatic beta cells: role for hepatocyte nuclear factor 3 beta and Pax6. *Mol. Cell Biol.* **22**: 4702–4713
- 128 Gerrish K., Gannon M., Shih D., Henderson E., Stoffel M., Wright C. V. et al. (2000) Pancreatic beta cell-specific transcription of the pdx-1 gene. The role of conserved upstream control regions and their hepatic nuclear factor 3 beta sites. *J. Biol. Chem.* **275**: 3485–3492
- 129 Wu K. L., Gannon M., Peshavaria M., Offield M. F., Henderson E., Ray M. et al. (1997) Hepatocyte nuclear factor 3 beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene. *Mol. Cell. Biol.* **17**: 6002–6013
- 130 Ben-Shushan E., Marshak S., Shoshkes M., Cerasi E., Melloul D. (2001) A pancreatic beta -cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3 beta (HNF-3 beta), HNF-1 alpha, and SPs transcription factors. *J. Biol. Chem.* **276**: 17533–17540
- 131 Cockell M., Stolarczyk D., Frutiger S., Hughes G. J., Hagenbuchle O., Wellauer P. K. (1995) Binding sites for hepatocyte nuclear factor 3 beta or 3 gamma and pancreas transcription factor 1 are required for efficient expression of the gene encoding pancreatic alpha-amylase. *Mol. Cell. Biol.* **15**: 1933–1941
- 132 Clark K. L., Halay E. D., Lai E., Burley S. K. (1993) Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. *Nature* **364**: 412–420
- 133 Brennan R. G. (1993) The winged-helix DNA-binding motif: another helix-turn-helix takeoff. *Cell* **74**: 773–776
- 134 Overdier D. G., Porcella A., Costa R. H. (1994) The DNA-binding specificity of the hepatocyte nuclear factor 3/forkhead domain is influenced by amino-acid residues adjacent to the recognition helix. *Mol. Cell. Biol.* **14**: 2755–2766
- 135 Liu Y., Shen W., Brubaker P. L., Kaestner K. H., Drucker D. J. (2002) Foxa3 (HNF-3 gamma) binds to and activates the rat proglucagon gene promoter but is not essential for proglucagon gene expression. *Biochem. J.* **366**: 633–641
- 136 Shen W., Searce L. M., Brestelli J. E., Sund N. J., Kaestner K. H. (2001) Foxa3 (hepatocyte nuclear factor 3 gamma) is required for the regulation of hepatic GLUT2 expression and the maintenance of glucose homeostasis during a prolonged fast. *J. Biol. Chem.* **276**: 42812–42817
- 137 Winter W. E., Nakamura M., House D. V. (1999) Monogenic diabetes mellitus in youth. The MODY syndromes. *Endocrinol. Metab. Clin. North Am.* **28**: 765–785

- 138 Winter W. E., Silverstein J. H. (2000) Molecular and genetic bases for maturity onset diabetes of youth. *Curr. Opin. Pediatr.* **12**: 388–393
- 139 Froguel P., Velho G. (1999) Molecular genetics of maturity-onset diabetes of the young. *Trends Endocrinol. Metab.* **10**: 142–146
- 140 Dabeva M. D., Hurston E., Sharitz D. A. (1995) Transcription factor and liver-specific mRNA expression in facultative epithelial progenitor cells of liver and pancreas. *Am. J. Pathol.* **147**: 1633–1648
- 141 Mendel D. B., Crabtree G. R. (1991) HNF-1, a member of a novel class of dimerizing homeodomain proteins. *J. Biol. Chem.* **266**: 677–680
- 142 Frain M., Swart G., Monaci P., Nicosia A., Stampfli S., Frank R. et al. (1989) The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. *Cell* **59**: 145–157
- 143 Bach I., Mattei M. G., Cereghini S., Yaniv M. (1991) Two members of an HNF1 homeoprotein family are expressed in human liver. *Nucleic Acids Res.* **19**: 3553–3559
- 144 Barbacci E., Reber M., Ott M. O., Breillat C., Huetz F., Cereghini S. (1999) Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification. *Development* **126**: 4795–4805
- 145 Coffinier C., Thepot D., Babinet C., Yaniv M., Barra J. (1999) Essential role for the homeoprotein vHNF1/HNF1 beta in visceral endoderm differentiation. *Development* **126**: 4785–4794
- 146 Coffinier C., Gresh L., Fiette L., Tronche F., Schutz G., Babinet C. et al. (2002) Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1 beta. *Development* **129**: 1829–1838
- 147 Sun Z., Hopkins N. (2001) *vhnf1*, the *MODY5* and familial GCKD-associated gene, regulates regional specification of the zebrafish gut, pronephros and hindbrain. *Genes Dev.* **15**: 3217–3229
- 148 Weng J. P., Lehto M., Forsblom C., Huang X., Li H., Groop L. C. (2000) Hepatocyte nuclear factor-1 beta (*MODY5*) gene mutations in Scandinavian families with early-onset diabetes or kidney disease or both. *Diabetologia* **43**: 131–132
- 149 Lindner T. H., Njolstad P. R., Horikawa Y., Bostad L., Bell Coffinier C., Thepot D. et al. (1999) Essential role for the homeoprotein vHNF1/HNF1 beta in visceral endoderm differentiation. *Development* **26**: 4785–4794
- 150 G. I., Sovik O. (1999) A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1 beta. *Hum. Mol. Genet.* **8**: 2001–2008
- 151 Horikawa Y., Iwasaki N., Hara M., Furuta H., Hinokio Y., Cockburn B. N. et al. (1997) Mutation in hepatocyte nuclear factor-1 beta gene (*TCF2*) associated with *MODY*. *Nat. Genet.* **17**: 384–385
- 152 Ek J., Grarup N., Urhammer S. A., Gaede P. H., Drivsholm T., Borch-Johnsen K. et al. (2001) Studies of the variability of the hepatocyte nuclear factor-1 beta (*HNF-1 beta/TCF2*) and the dimerization cofactor of *HNF-1 (DcoH/PCBD)* genes in relation to type 2 diabetes mellitus and beta-cell function. *Hum. Mutat.* **18**: 356–357
- 153 Thomas H., Jaschowitz K., Bulman M., Frayling T. M., Mitchell S. M., Roosen S. et al. (2001) A distant upstream promoter of the *HNF-4 alpha* gene connects the transcription factors involved in maturity-onset diabetes of the young. *Hum. Mol. Genet.* **10**: 2089–2097
- 154 Rey-Campos J., Chouard T., Yaniv M., Cereghini S. (1991) vHNF1 is a homeoprotein that activates transcription and forms heterodimers with HNF1. *EMBO J.* **10**: 1445–1457
- 155 Chouard T., Blumenfeld M., Bach I., Vandekerckhove J., Cereghini S., Yaniv M. (1990) A distal dimerization domain is essential for DNA-binding by the atypical HNF1 homeodomain. *Nucleic Acids Res.* **18**: 5853–5863
- 156 Okita K., Yang Q., Yamagata K., Hangenfeldt K. A., Miyagawa J., Kajimoto Y. et al. (1999) Human insulin gene is a target gene of hepatocyte nuclear factor-1 alpha (*HNF-1 alpha*) and *HNF-1 beta*. *Biochem. Biophys. Res. Commun.* **263**: 566–569
- 157 Li J., Ning G., Duncan S. A. (2000) Mammalian hepatocyte differentiation requires the transcription factor *HNF-4 alpha*. *Genes Dev.* **14**: 464–474
- 158 Kuo C. J., Conley P. B., Chen L., Sladek F. M., Darnell J. E. Jr, Crabtree G. R. (1992) A transcriptional hierarchy involved in mammalian cell-type specification. *Nature* **355**: 457–461
- 159 Tian J. M., Schibler U. (1991) Tissue-specific expression of the gene encoding hepatocyte nuclear factor 1 may involve hepatocyte nuclear factor 4. *Genes Dev.* **5**: 2225–2234
- 160 Shih D. Q., Heimesaat M., Kuwajima S., Stein R., Wright C. V., Stoffel M. (2002) Profound defects in pancreatic beta-cell function in mice with combined heterozygous mutations in *Pdx-1*, *Hnf-1 alpha* and *Hnf-3 beta*. *Proc. Natl. Acad. Sci. USA* **99**: 3818–3823
- 161 Yamagata K., Nammo T., Moriwaki M., Ihara A., Iizuka K., Yang Q. et al. (2002) Overexpression of dominant-negative mutant hepatocyte nuclear factor-1 alpha in pancreatic beta-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced beta-cell proliferation, and diabetes. *Diabetes* **51**: 114–123
- 162 Wobser H., Dussmann H., Kogel D., Wang H., Reimertz C., Wollheim C. B. et al. (2002) Dominant-negative suppression of *HNF-1 alpha* results in mitochondrial dysfunction, *INS-1* cell apoptosis, and increased sensitivity to ceramide-, but not to high glucose-induced cell death. *J. Biol. Chem.* **277**: 6413–6421
- 163 Hagenfeldt-Johansson K. A., Herrera P. L., Wang H., Gjinovci A., Ishihara H., Wollheim C. B. (2001) Beta-cell-targeted expression of a dominant-negative hepatocyte nuclear factor-1 alpha induces a maturity-onset diabetes of the young (*MODY*)3-like phenotype in transgenic mice. *Endocrinology* **142**: 5311–5320
- 164 Lee Y. H., Sauer B., Gonzalez F. J. (1998) Laron dwarfism and non-insulin-dependent diabetes mellitus in the *Hnf-1 alpha* knockout mouse. *Mol. Cell. Biol.* **18**: 3059–3068
- 165 Pontoglio M., Sreenan S., Roe M., Pugh W., Ostrega D., Doyen A. et al. (1998) Defective insulin secretion in hepatocyte nuclear factor 1 alpha-deficient mice. *J. Clin. Invest.* **101**: 2215–2222
- 166 Dukes I. D., Sreenan S., Roe M. W., Levisetti M., Zhou Y. P., Ostrega D. et al. (1998) Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1 alpha-deficient mice. *J. Biol. Chem.* **273**: 24457–24464
- 167 Wang H., Maechler P., Hagenfeldt K. A., Wollheim C. B. (1998) Dominant-negative suppression of *HNF-1 alpha* function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. *EMBO J.* **17**: 6701–6713
- 168 Yamada S., Nishigori H., Onda H., Utsugi T., Yanagawa T., Maruyama T. et al. (1997) Identification of mutations in the hepatocyte nuclear factor (*HNF*)-1 alpha gene in Japanese subjects with *IDDM*. *Diabetes* **46**: 1643–1647
- 169 Pontoglio M., Barra J., Hadchouel M., Doyen A., Kress C., Bach J. P. et al. (1996) Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. *Cell* **84**: 575–585
- 170 Hiemisch H., Schutz G., Kaestner K. H. (1997) Transcriptional regulation in endoderm development: characterization of an enhancer controlling *Hnf3g* expression by transgenesis and targeted mutagenesis. *EMBO J.* **16**: 3995–4006
- 171 Emens L. A., Landers D. W., Moss L. G. (1992) Hepatocyte nuclear factor 1 alpha is expressed in a hamster insulinoma line and transactivates the rat insulin I gene. *Proc. Natl. Acad. Sci. USA* **89**: 7300–7304

- 172 Tronche F., Ringeisen F., Blumenfeld M., Yaniv M., Pontoglio M. (1997) Analysis of the distribution of binding sites for a tissue-specific transcription factor in the vertebrate genome. *J. Mol. Biol.* **266**: 231–245
- 173 Cereghini S., Blumenfeld M., Yaniv M. (1988) A liver-specific factor essential for albumin transcription differs between differentiated and dedifferentiated rat hepatoma cells. *Genes Dev.* **2**: 957–974
- 174 Shih D. Q., Screenan S., Munoz K. N., Philipson L., Pontoglio M., Yaniv M. et al. (2001) Loss of HNF-1 alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. *Diabetes* **50**: 2472–2480
- 175 Ban N., Yamada Y., Someya Y., Miyawaki K., Ihara Y., Hosokawa M. et al. (2002) Hepatocyte nuclear factor-1 alpha recruits the transcriptional co-activator p300 on the GLUT2 gene promoter. *Diabetes* **51**: 1409–1418
- 176 Sladek F. M., Zhong W. M., Lai E., Darnell J. E. Jr (1990) Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. *Genes Dev.* **4**: 2353–2365
- 177 Drewes T., Senkel S., Holewa B., Ryffel G. U. (1996) Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. *Mol. Cell. Biol.* **16**: 925–931
- 178 Kritis A. A., Argyrokastritis A., Moschonas N. K., Power S., Katrakili N., Zannis V. I. et al. (1996) Isolation and characterization of a third isoform of human hepatocyte nuclear factor 4. *Gene* **173**: 275–280
- 179 Holewa B., Zapp D., Drewes T., Senkel S., Ryffel G. U. (1997) HNF4beta, a new gene of the HNF4 family with distinct activation and expression profiles in oogenesis and embryogenesis of *Xenopus laevis*. *Mol. Cell. Biol.* **17**: 687–694
- 180 Taraviras S., Mantamadiotis T., Dong-Si T., Mincheva A., Lichter P., Drewes T. et al. (2000) Primary structure, chromosomal mapping, expression and transcriptional activity of murine hepatocyte nuclear factor 4gamma. *Biochim. Biophys. Acta.* **1490**: 21–32
- 181 Jiang G., Nepomuceno L., Hopkins K., Sladek F. M. (1995) Exclusive homodimerization of the orphan receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors. *Mol. Cell. Biol.* **15**: 5131–5143
- 182 Sladek F. M. (1994) Orphan receptor HNF-4 and liver-specific gene expression. *Receptor* **4**: 64
- 183 Viollet B., Kahn A., Raymondjean M. (1997) Protein kinase A-dependent phosphorylation modulates DNA-binding activity of hepatocyte nuclear factor 4. *Mol. Cell. Biol.* **17**: 4208–4219
- 184 Eeckhoutte J., Formstecher P., Laine B. (2001) Maturity-onset diabetes of the young Type 1 (MODY1)-associated mutations R154X and E276Q in hepatocyte nuclear factor 4alpha (HNF4alpha) gene impair recruitment of p300, a key transcriptional co-activator. *Mol. Endocrinol.* **15**: 1200–1210
- 185 Chen W. S., Manova K., Weinstein D. C., Duncan S. A., Plump A. S., Prezioso V. R. et al. (1994) Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. *Genes Dev.* **8**: 2466–2477
- 186 Duncan S. A., Manova K., Chen W. S., Hoodless P., Weinstein D. C., Bachvarova R. F. et al. (1994) Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst. *Proc. Natl. Acad. Sci. USA* **91**: 7598–7602
- 187 Duncan S. A., Nagy A., Chan W. (1997) Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of *Hnf-4(-/-)* embryos. *Development* **124**: 279–287
- 188 Miquerol L., Lopez S., Cartier N., Tulliez M., Raymondjean M., Kahn A. (1994) Expression of the L-type pyruvate kinase gene and the hepatocyte nuclear factor 4 transcription factor in exocrine and endocrine pancreas. *J. Biol. Chem.* **269**: 8944–8951
- 189 Yamagata K., Furuta H., Oda N., Kaisaki P. J., Menzel S., Cox N. J. et al. (1996) Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1) *Nature* **384**: 458–460
- 190 Nakajima H., Yoshiuchi I., Hamaguchi T., Tomita K., Yamasaki T., Iizuka K. et al. (1996) Hepatocyte nuclear factor-4 alpha gene mutations in Japanese non-insulin dependent diabetes mellitus (NIDDM) patients. *Res. Commun. Mol. Pathol. Pharmacol.* **94**: 327–330
- 191 Furuta H., Iwasaki N., Oda N., Hinokio Y., Horikawa Y., Yamagata K. et al. (1997) Organization and partial sequence of the hepatocyte nuclear factor-4 alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY. *Diabetes* **46**: 1652–1657
- 192 Rajas F., Gautier A., Bady I., Montano S., Mithieux G (2002) Polyunsaturated fatty acyl coenzyme A suppress the glucose-6-phosphatase promoter activity by modulating the DNA binding of hepatocyte nuclear factor 4 alpha. *J. Biol. Chem.* **277**: 15736–15744
- 193 Tian J. M., Schibler U. (1991) Tissue-specific expression of the gene encoding hepatocyte nuclear factor 1 may involve hepatocyte nuclear factor 4. *Genes Dev.* **5**: 2225–2234
- 194 Wang H., Maechler P., Antinozzi P. A., Hagenfeldt K. A., Wollheim C. B. (2000) Hepatocyte nuclear factor 4alpha regulates the expression of pancreatic beta-cell genes implicated in glucose metabolism and nutrient-induced insulin secretion. *J. Biol. Chem.* **275**: 35953–35959
- 195 Bartoov-Shifman R., Hertz R., Wang H., Wollheim C. B., Bartana J., Walker M. D. (2002) Activation of the insulin gene promoter through a direct effect of hepatocyte nuclear factor 4 alpha. *J. Biol. Chem.* **277**: 25914–25919
- 196 St-Onge L., Wehr R., Gruss P. (1999) Pancreas development and diabetes. *Curr. Opin. Genet. Dev.* **9**: 295–300
- 197 Mansouri A., St-Onge L., Gruss P. (1999) Role of genes in endoderm-derived organs. *Trends Endocrinol. Metab.* **10**: 164–167
- 198 Dohrmann C., Gruss P., Lemaire L. (2000) Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas. *Mech. Dev.* **92**: 47–54
- 199 Larsson L. I., St-Onge L., Hougaard D. M., Sosa-Pineda B., Gruss P. (1998) Pax 4 and 6 regulate gastrointestinal endocrine cell development. *Mech. Dev.* **79**: 153–159
- 200 Sander M., Neubuser A., Kalamaras J., Ee H. C., Martin G. R., German M. S. (1997) Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. *Genes Dev.* **11**: 1662–1673
- 201 Tokuyama Y., Yagui K., Sakurai K., Hashimoto N., Saito Y., Kanatsuka A. (1998) Molecular cloning of rat Pax4: identification of four isoforms in rat insulinoma cells. *Biochem. Biophys. Res. Commun.* **248**: 153–156
- 202 Miyamoto T., Kakizawa T., Ichikawa K., Nishio S., Kajikawa S., Hashizume K. (2001) Expression of dominant negative form of PAX4 in human insulinoma. *Biochem. Biophys. Res. Commun.* **282**: 34–40
- 203 Smith S. B., Ee H. C., Conners J. R., German M. S. (1999) Paired-homeodomain transcription factor PAX4 acts as a transcriptional repressor in early pancreatic development. *Mol. Cell. Biol.* **19**: 8272–8280
- 204 Fujitani Y., Kajimoto Y., Yasuda T., Matsuoka T. A., Kaneto H., Umayahara Y. et al. (1999) Identification of a portable repression domain and an E1A-responsive activation domain in Pax4: a possible role of Pax4 as a transcriptional repressor in the pancreas. *Mol. Cell. Biol.* **19**: 8281–8291
- 205 Campbell S. C., Cragg H., Elrick L. J., Macfarlane W. M., Shennan K. I., Docherty K. (1999) Inhibitory effect of pax4 on

- the human insulin and islet amyloid polypeptide (IAPP) promoters. *FEBS Lett.* **463**: 53–57
- 206 Petersen H. V., Jorgensen M. C., Andersen F. G., Jensen J., F-Nielsen T., Jorgensen R. et al. (2000) Pax4 represses pancreatic glucagon gene expression. *Mol. Cell. Biol. Res. Commun.* **3**: 249–254
- 207 Ritz-Laser B., Estreicher A., Gauthier B. R., Mamin A., Edlund H., Philippe J. (2002) The pancreatic beta-cell-specific transcription factor Pax-4 inhibits glucagon gene expression through Pax-6. *Diabetologia* **45**: 97–107
- 208 Kalousova A., Benes V., Paces J., Paces V., Kozmik Z. (1999) DNA binding and transactivating properties of the paired and homeobox protein Pax4. *Biochem. Biophys. Res. Commun.* **259**: 510–518
- 209 Epstein J., Cai J., Glaser T., Jepeal L., Maas R. (1994) Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes. *J. Biol. Chem.* **269**: 8355–8361
- 210 Czerny T., Busslinger M. (1995) DNA-binding and transactivation properties of Pax-6: three amino acids in the paired domain are responsible for the different sequence recognition of Pax-6 and BSAP (Pax-5). *Mol. Cell. Biol.* **15**: 2858–2871
- 211 Zhou Y., Zheng J. B., Gu X., Li W., Saunders G. F. (2000) A novel Pax-6 binding site in rodent B1 repetitive elements: co-evolution between developmental regulation and repeated elements? *Gene* **245**: 319–328
- 212 Planque N., Leconte L., Coquelle F. M., Benkhelifa S., Martin P., Felder-Schmittbuhl M. P. et al. (2001) Interaction of Maf transcription factors with Pax-6 results in synergistic activation of the glucagon promoter. *J. Biol. Chem.* **276**: 35751–35760
- 213 Ritz-Laser B., Estreicher A., Klages N., Saule S., Philippe J. (1999) Pax-6 and Cdx-2/3 interact to activate glucagon gene expression on the G1 control element. *J. Biol. Chem.* **274**: 4124–4132
- 214 Andersen F. G., Heller R. S., Petersen H. V., Jensen J., Madsen O. D., Serup P. (1999) Pax6 and Cdx2/3 form a functional complex on the rat glucagon gene promoter G1-element. *FEBS Lett.* **445**: 306–310
- 215 Hussain M. A., Habener J. F. (1999) Glucagon gene transcription activation mediated by synergistic interactions of pax-6 and cdx-2 with the p300 co-activator. *J. Biol. Chem.* **274**: 28950–28957
- 216 Grzeskowiak R., Amin J., Oetjen E., Knepel W. (2000) Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer-like elements involving the paired-domain transcription factor Pax6. *J. Biol. Chem.* **275**: 30037–30045
- 217 Beimesche S., Neubauer A., Herzig S., Grzeskowiak R., Diedrich T., Cierny I. et al. (1999) Tissue-specific transcriptional activity of a pancreatic islet cell-specific enhancer sequence/Pax6-binding site determined in normal adult tissues in vivo using transgenic mice. *Mol. Endocrinol.* **13**: 718–728
- 218 Hill M. E., Asa S. L., Drucker D. J. (1999) Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. *Mol. Endocrinol.* **13**: 1474–1486
- 219 Ritz-Laser B., Estreicher A., Gauthier B., Philippe J. (2000) The paired homeodomain transcription factor Pax-2 is expressed in the endocrine pancreas and transactivates the glucagon gene promoter. *J. Biol. Chem.* **275**: 32708–32715
- 220 Phelps D. E., Dressler G. R. (1996) Identification of novel Pax-2 binding sites by chromatin precipitation. *J. Biol. Chem.* **271**: 7978–7985
- 221 Epstein J., Cai J., Glaser T., Jepeal L., Maas R. (1994) Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes. *J. Biol. Chem.* **269**: 8355–8361
- 222 Havik B., Ragnhildstveit E., Lorens J. B., Saelemyr K., Fauske O., Knudsen L. K. et al. (1999) A novel paired domain DNA recognition motif can mediate Pax2 repression of gene transcription. *Biochem. Biophys. Res. Commun.* **266**: 532–541
- 223 Inoue H., Rudnick A., German M. S., Veile R., Donis-Keller H., Permutt M. A. (1997) Isolation, characterization, and chromosomal mapping of the human Nkx6.1 gene (NKX6A), a new pancreatic islet homeobox gene. *Genomics* **40**: 367–370
- 224 Kim Y., Nirenberg M. (1989) *Drosophila* NK-homeobox genes. *Proc. Natl. Acad. Sci. USA* **86**: 7716–7720
- 225 Watada H., Mirmira R. G., Leung J., German M. S. (2000) Transcriptional and translational regulation of beta-cell differentiation factor Nkx6.1. *J. Biol. Chem.* **275**: 34224–34230
- 226 Jorgensen M. C., Vestergard Petersen H., Ericson J., Madsen O. D., Serup P. (1999) Cloning and DNA-binding properties of the rat pancreatic beta-cell-specific factor Nkx6.1. *FEBS Lett.* **461**: 287–294
- 227 Li H., Arber S., Jessell T. M., Edlund H. (1999) Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9. *Nat. Genet.* **23**: 67–70
- 228 Harrison K. A., Thaler J., Pfaff S. L., Gu H., Kehrl J. H. (1999) Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-deficient mice. *Nat. Genet.* **23**: 71–75
- 229 Li H., Edlund H. (2001) Persistent expression of Hlxb9 in the pancreatic epithelium impairs pancreatic development. *Dev. Biol.* **240**: 247–253
- 230 Catala M. (2002) Genetic control of caudal development. *Clin. Genet.* **61**: 89–96
- 231 Ahlgren U., Pfaff S. L., Jessell T. M., Edlund T., Edlund H. (1997) Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. *Nature* **385**: 257–260
- 232 Shimomura H., Sanke T., Hanabusa T., Tsunoda K., Furuta H., Nanjo K. (2000) Nonsense mutation of islet-1 gene (Q310X) found in a type 2 diabetic patient with a strong family history. *Diabetes* **49**: 1597–1600
- 233 Karlsson O., Thor S., Norberg T., Ohlsson H., Edlund T. (1990) Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. *Nature* **344**: 879–882
- 234 Vallejo M., Penchuk L., Habener J. F. (1992) Somatostatin gene upstream enhancer element activated by a protein complex consisting of CREB, Isl-1-like and alpha-CBF-like transcription factors. *J. Biol. Chem.* **267**: 12876–12884
- 235 Leonard J., Serup P., Gonzalez G., Edlund T., Montminy M. (1992) The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells. *Proc. Natl. Acad. Sci. USA* **89**: 6247–6251
- 236 Wang M., Drucker D. J. (1996) Activation of amylin gene transcription by LIM domain homeobox gene isl-1. *Mol. Endocrinol.* **10**: 243–251
- 237 Wang M., Drucker D. J. (1995) The LIM domain homeobox gene isl-1 is a positive regulator of islet cell-specific proglucagon gene transcription. *J. Biol. Chem.* **270**: 12646–12652
- 238 van den Akker E., Forlani S., Chawengsaksophak K., de Graaff W., Beck F., Meyer B. I. et al. (2002) Cdx1 and Cdx2 have overlapping functions in anteroposterior patterning and posterior axis elongation. *Development* **129**: 2181–2193
- 239 Chawengsaksophak K., James R., Hammond V. E., Kontgen F., Beck F. (1997) Homeosis and intestinal tumours in Cdx2 mutant mice. *Nature* **386**: 84–87
- 240 Freund J. N., Domon-Dell C., Kedinger M., Duluc I. (1998) The Cdx-1 and Cdx-2 homeobox genes in the intestine. *Biochem. Cell. Biol.* **76**: 957–969
- 241 Suh E., Chen L., Taylor J., Traber P. G. (1994) A homeodomain protein related to caudal regulates intestine-specific gene transcription. *Mol. Cell. Biol.* **14**: 7340–7351
- 242 Jin T., Li H. (2001) Pou homeodomain protein OCT1 is implicated in the expression of the caudal-related homeobox gene Cdx-2. *J. Biol. Chem.* **276**: 14752–14758

- 243 Xu F., Li H., Jin T. (1999) Cell type-specific autoregulation of the Caudal-related homeobox gene *Cdx-2/3*. *J. Biol. Chem.* **274**: 34310–34316
- 244 Trinh K. Y., Jin T., Drucker D. J. (1999) Identification of domains mediating transcriptional activation and cytoplasmic export in the caudal homeobox protein *Cdx-3*. *J. Biol. Chem.* **274**: 6011–6019
- 245 Hussain M. A., Habener J. F. (1999) Glucagon gene transcription activation mediated by synergistic interactions of *pax-6* and *cdx-2* with the p300 co-activator. *J. Biol. Chem.* **274**: 28950–28957
- 246 Jin T., Trinh D. K., Wang F., Drucker D. J. (1997) The caudal homeobox protein *cdx-2/3* activates endogenous proglucagon gene expression in InR1-G9 islet cells. *Mol. Endocrinol.* **11**: 203–209
- 247 Jin T., Drucker D. J. (1996) Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein *cdx-2/3*. *Mol. Cell. Biol.* **16**: 19–28
- 248 Laser B., Meda P., Constant I., Philippe J. (1996) The caudal-related homeodomain protein *Cdx-2/3* regulates glucagon gene expression in islet cells. *J. Biol. Chem.* **271**: 28984–28994
- 249 German M. S., Wang J., Chadwick R. B., Rutter W. J. (1992) Synergistic activation of the insulin gene by a LIM-homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer complex. *Genes Dev.* **6**: 2165–2176
- 250 Troelsen J. T., Mitchelmore C., Spodsberg N., Jensen A. M., Noren O., Sjoström H. (1997) Regulation of lactase-phlorizin hydrolase gene expression by the caudal-related homeodomain protein *Cdx-2*. *Biochem. J.* **322**: 833–838
- 251 Drummond F. J., Sowden J., Morrison K., Edwards Y. H. (1998) Colon carbonic anhydrase 1: transactivation of gene expression by the homeodomain protein *Cdx2*. *FEBS Lett.* **423**: 218–222
- 252 Lambert M., Colnot S., Suh E., L'Horset F., Blin C., Calliot M. E. et al. (1996) cis-Acting elements and transcription factors involved in the intestinal specific expression of the rat calbindin-D9K gene: binding of the intestine-specific transcription factor *Cdx-2* to the TATA box. *Eur. J. Biochem.* **236**: 778–788
- 253 Colnot S., Romagnolo B., Lambert M., Cluzeaud F., Porteu A., Vandewalle A. et al. (1998) Intestinal expression of the calbindin-D9K gene in transgenic mice. Requirement for a *Cdx2*-binding site in a distal activator region. *J. Biol. Chem.* **273**: 31939–31946
- 254 Taylor J. K., Levy T., Suh E. R., Traber P. G. (1997) Activation of enhancer elements by the homeobox gene *Cdx2* is cell line specific. *Nucleic Acids Res.* **25**: 2293–2300
- 255 Matthew D., Di Guglielmo M. D., Park J., Schulz S., Waldman S. A. (2001) Nucleotide requirements for *CDX2* binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C. *FEBS Lett.* **507**: 128–132
- 256 Lambert M., Colnot S., Suh E., L'Horset F., Blin C., Calliot M. E. et al. (1996) cis-Acting elements and transcription factors involved in the intestinal specific expression of the rat calbindin-D9K gene: binding of the intestine-specific transcription factor *Cdx-2* to the TATA box. *Eur. J. Biochem.* **236**: 778–788
- 257 Arai H., Miyamoto K. I., Yoshida M., Yamamoto H., Taketani Y., Morita K. et al. (2001) The polymorphism in the caudal-related homeodomain protein *Cdx-2* binding element in the human vitamin D receptor gene. *J. Bone Miner. Res.* **16**: 1256–1264
- 258 Yamamoto H., Miyamoto K., Li B., Taketani Y., Kitano M., Inoue Y. et al. (1999) The caudal-related homeodomain protein *Cdx-2* regulates vitamin D receptor gene expression in the small intestine. *J. Bone Miner. Res.* **14**: 240–247
- 259 Mitchelmore C., Troelsen J. T., Spodsberg N., Sjoström H., Noren O. (2000) Interaction between the homeodomain proteins *Cdx2* and *HNF1 alpha* mediates expression of the lactase-phlorizin hydrolase gene. *Biochem. J.* **346**: 529–535
- 260 Reza H. M., Ogino H., Yasuda K. (2002) *L-Maf*, a downstream target of *Pax6*, is essential for chick lens development. *Mech. Dev.* **116**: 61–73
- 261 Benkhelifa S., Provot S., Nabais E., Eychene A., Calothy G., Felder-Schmittbuhl M. P. (2001) Phosphorylation of *MafA* is essential for its transcriptional and biological properties. *Mol. Cell. Biol.* **21**: 4441–4452
- 262 Olbrot M., Rud J., Moss L. G., Sharma A. (2002) Identification of beta-cell-specific insulin gene transcription factor *RIPE3b1* as mammalian *MafA*. *Proc. Natl. Acad. Sci. USA* **99**: 6737–6742



To access this journal online:
<http://www.birkhauser.ch>
